Ocugen(OCGN) - 2024 Q2 - Quarterly Results

Exhibit 99.1 Ocugen Provides Business Update with Second Quarter 2024 Financial Results Conference Call and Webcast Today at 8:30 a.m. ET • Actively dosing patients in OCU400 Phase 3 liMeliGhT clinical trial • OCU410 preliminary safety and ef icacy data expected later this year • Expanded access program approved for OCU400 • $32.6 million net cash from underwritten public of ering of common stock MALVERN, Pa., August 8, 2024 (GLOBE NEWSWIRE) – Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechno ...